Related Experiment Video
Updated: Jul 12, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Clinical trials in systemic sclerosis: lessons learned and outcomes
Marco Matucci-Cerinic1, Virginia D Steen, Daniel E Furst
1Division of Medicine and Surgery, Division of Medicine I and Rheumatology, Villa Monna Tessa, Viale Pieraccini, I-50139 Florence, Italy. cerinic@unifi.it
Arthritis Research & Therapy
|September 15, 2007
Summary
Systemic sclerosis (SSc) diagnosis and treatment present challenges due to disease complexity and heterogeneity. Reviewing clinical trials and registries aids in refining outcome measures for better early treatment efficacy in SSc.
Area of Science:
- Rheumatology
- Immunology
- Clinical Trial Design
Background:
- Systemic sclerosis (SSc) pathogenesis is complex and poorly understood.
- Clinical heterogeneity and long progression complicate clinical trial endpoint selection.
- Early diagnosis and identification of patients benefiting from aggressive treatment are crucial for altering disease course.
Purpose of the Study:
- To review data from recent clinical trials and observational studies.
- To derive lessons for improving the understanding of SSc clinical course.
- To refine outcome measures for future clinical trial design.
Main Methods:
- Review of recent clinical trial data.
- Analysis of retrospective observational studies.
- Examination of patient registries and databases.
Main Results:
- Observations provide insights into the diverse clinical course of SSc.
- Lessons learned can inform better clinical trial design.
- Refinement of outcome measures can maximize the potential for observing treatment effects.
Conclusions:
- Improved understanding of SSc progression is essential.
- Optimized outcome measures are needed for effective clinical trials.
- Future trials require refined strategies to demonstrate treatment efficacy in SSc.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...